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Corrigendum
Correction concerning Norden T, Lindgren A, Bergstrom R,
Holmberg L. 'Defining a high mortality risk group among
women with primary breast cancer', Br. J. Cancer (1994) 69,
520-524.
Included in this paper is the elaboration of prognostic
indices, with the main interest devoted to node-negative
patients with poor prognosis. We have discovered an error,
although we have no strong reason to believe that it would
influence the results. However, since we specifically stated
that we studied women whom we judged not to have received
systemic adjuvant treatment (intake into the cohort was ter-
minated when adjuvant systemic treatment became a part of
the treatment protocol for the University Hospital), we wish
to make the following correction. The correction is focused
on the factor in the index where prognostic value may have
been confounded by the use of, in particular, hormonal
treatment.
In other studies of prognostic factors, it was revealed that
some patients with node-positive disease received adjuvant
systemic therapy outside the official treatment protocol. A
random sample of individual records was studied. Adjuvant
treatment was first given after the publication of the NCI
documents in 1985 and 1986 and was not given to all women
with node-positive disease (N+). The sample shows that
65% ofpost-menopausal (N+) and nearly all premenopausal
(N+) women received adjuvant therapy. The treatments
given were tamoxifen 20-40 mg daily for post-menopausal
women and intranveous CMF for premenopausal women.
Of the total cohort of 525 women, 79 post-menopausal and
20 premenopausal women were classified as N+ after 1
January 1985. Thus, 50-55 of the post-menopausal and 20 of
the premenopausal women could have been treated
systemically. To analyse the possible influence of the treat-
ment on the results of our study, a number of complemen-
tary analyses were undertaken. The performance of the
indices did not change when analysed by time period (before
or after 1 January 1985). Multivariate Cox proportional
hazards models (correcting for age at diagnosis, tumour
diameter, histopathological type and DNA ploidy) did not
reveal any pattern ofconfounding by the adjuvant treatment.
The interaction term between oestrogen receptor status and
diagnosis after 1 January 1985 was numerically small and far
from statistically significant (Table I).
In conclusion, adjuvant treatment was given to few
patients in the total cohort. Complementary analyses indicate
that treatment of even so few patients does not confound our
results, not even when we look specifically at the factor in the
index of major concern, the oestrogen receptor value.
Table I Cox proportional hazards model taking receptor status and
period of diagnosis into account (corrected for node status, age at
diagnosis, tumour diameter, histopathological classification and
DNA ploidy)
Relative hazard P-value
ER- vs ER' 1.4 0.12
PR- vs PR' 1.4 0.04
Diagnosis >85 1.4 0.29
ER*Diagnosis>85 0.9 0.94
ER, oestrogen receptor; PR, progesterone receptor; Diagnosis>85,
diagnosis after 1 January 1985; ER*Diagnosis>85, interaction term
between oestrogen receptor status and time of diagnosis.